BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35452014)

  • 21. Chemokine receptor-4 targeted PET/CT with
    Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [
    Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New types of localization methods for adrenocorticotropic hormone-dependent Cushing's syndrome.
    Senanayake R; Gillett D; MacFarlane J; Van de Meulen M; Powlson A; Koulouri O; Casey R; Bashari W; Gurnell M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101513. PubMed ID: 34045044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
    Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
    Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
    J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of fluorine-18-fluorodeoxyglucose PET/CT in localizing the primary lesion in adrenocorticotropic hormone-dependent Cushing syndrome.
    Zhou J; Ju H; Zhu L; Pan Y; Lv J; Zhang Y
    Nucl Med Commun; 2019 May; 40(5):539-544. PubMed ID: 30973841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cortisol-Producing Adrenal Adenomas With Intense Activity on 68Ga-Pentixafor PET/CT.
    Ding J; Tong A; Zhang Y; Zhang H; Huo L
    Clin Nucl Med; 2021 Apr; 46(4):350-352. PubMed ID: 33492858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCR4 PET imaging of mantle cell lymphoma using [
    Mayerhoefer ME; Raderer M; Lamm W; Pichler V; Pfaff S; Weber M; Kiesewetter B; Hacker M; Kazianka L; Staber PB; Wester HJ; Rohrbeck J; Simonitsch-Klupp I; Haug A
    Theranostics; 2021; 11(2):567-578. PubMed ID: 33391493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
    Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
    Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cushing syndrome: pituitary CT scanning.
    Saris SC; Patronas NJ; Doppman JL; Loriaux DL; Cutler GB; Nieman LK; Chrousos GP; Oldfield EH
    Radiology; 1987 Mar; 162(3):775-7. PubMed ID: 3809493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease.
    Ceccato F; Tizianel I; Vedolin CK; Boscaro M; Barbot M; Scaroni C
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32818260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [
    Lawal IO; Popoola GO; Mahapane J; Kaufmann J; Davis C; Ndlovu H; Maserumule LC; Mokoala KMG; Bouterfa H; Wester HJ; Zeevaart JR; Sathekge MM
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced splenic uptake on
    Kraus S; Klassen P; Kircher M; Dierks A; Habringer S; Gäble A; Kortüm KM; Weinhold N; Ademaj-Kospiri V; Werner RA; Schirbel A; Buck AK; Herhaus P; Wester HJ; Rosenwald A; Weber WA; Einsele H; Keller U; Rasche L; Lapa C
    Theranostics; 2022; 12(13):5986-5994. PubMed ID: 35966583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.
    Invitti C; Pecori Giraldi F; de Martin M; Cavagnini F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):440-8. PubMed ID: 10022398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4-directed PET/CT with [
    Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the performance of
    Yin X; Ai K; Luo J; Liu W; Ma X; Zhou L; Xiang X; Su X; Wang Y; Li Y
    Front Endocrinol (Lausanne); 2024; 15():1291775. PubMed ID: 38419957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenomas: An Underestimated Entity.
    Knappe UJ; Jaspers C; Buschsieweke D; Reinbold WD; Alomari A; Saeger W; Ehlenz K; Mann WA; Kann PH; Feldkamp J
    Neurosurgery; 2017 Apr; 80(4):525-533. PubMed ID: 27352274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 68 Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results.
    Jena SR; Watts A; Aggarwal P; Bachhal V; Kaur H; Dhingra K; Singh H; Bal A; Singh B
    Nucl Med Commun; 2024 Mar; 45(3):229-235. PubMed ID: 38165171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [
    Chen Z; Yang A; Chen A; Dong J; Lin J; Huang C; Zhang J; Liu H; Zeng Z; Miao W
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1926-1936. PubMed ID: 38286937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism.
    Ding J; Zhang Y; Wen J; Zhang H; Wang H; Luo Y; Pan Q; Zhu W; Wang X; Yao S; Kreissl MC; Hacker M; Tong A; Huo L; Li X
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2656-2665. PubMed ID: 32206838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.